KRW 27400.0
(-5.03%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 160.14 Billion KRW | -13.52% |
2022 | 185.18 Billion KRW | 182.92% |
2021 | 65.45 Billion KRW | -34.48% |
2020 | 99.89 Billion KRW | -30.1% |
2019 | 142.9 Billion KRW | -15.38% |
2018 | 168.86 Billion KRW | 729.02% |
2017 | 20.36 Billion KRW | 170.5% |
2016 | 7.53 Billion KRW | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 140.75 Billion KRW | -12.11% |
2024 Q2 | 120.71 Billion KRW | -14.24% |
2023 Q1 | 202.9 Billion KRW | 9.57% |
2023 Q4 | 160.14 Billion KRW | -8.33% |
2023 Q3 | 174.69 Billion KRW | -6.88% |
2023 Q2 | 187.6 Billion KRW | -7.54% |
2023 FY | 160.14 Billion KRW | -13.52% |
2022 Q1 | 147.97 Billion KRW | 126.08% |
2022 Q4 | 185.18 Billion KRW | 13.4% |
2022 Q3 | 163.29 Billion KRW | 10.63% |
2022 Q2 | 147.59 Billion KRW | -0.26% |
2022 FY | 185.18 Billion KRW | 182.92% |
2021 FY | 65.45 Billion KRW | -34.48% |
2021 Q2 | 85.24 Billion KRW | -9.81% |
2021 Q4 | 65.45 Billion KRW | -14.44% |
2021 Q3 | 76.49 Billion KRW | -10.26% |
2021 Q1 | 94.51 Billion KRW | 0.0% |
2020 FY | 99.89 Billion KRW | -30.1% |
2019 FY | 142.9 Billion KRW | -15.38% |
2018 FY | 168.86 Billion KRW | 729.02% |
2017 FY | 20.36 Billion KRW | 170.5% |
2016 FY | 7.53 Billion KRW | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Sam Chun Dang Pharm. Co., Ltd | 408.02 Billion KRW | 60.751% |
Hyundai Bioscience Co., Ltd. | 52.79 Billion KRW | -203.351% |
ST Pharm Co.,Ltd. | 686.83 Billion KRW | 76.684% |
Cellid, Co., Ltd. | 63.92 Billion KRW | -150.53% |